MedPath

Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block

Phase 1
Completed
Conditions
Pain, Perioperative
Hip Fractures
Anesthesia Local
Interventions
Drug: Lidocaine-epinephrine added gadoterate meglumine
Registration Number
NCT02593370
Lead Sponsor
Thomas F. Bendtsen
Brief Summary

The main objective of the trial is to complete a double-blinded randomized controlled trial with crossover design of a lumbosacral plexus block with the Suprasacral Parallel Shift technique guided by ultrasound/magnetic resonance (MR) image fusion vs. Suprasacral Parallel Shift guided by ultrasound by estimating sensory block of the femoral nerve, the obturator nerve, the lumbosacral trunk, and spinal nerve L1 in healthy volunteers.

Detailed Description

The main objective of the trial is to complete a double-blinded randomized controlled trial with crossover design of a one-injection nerve block of the lower part of the lumbar plexus and the upper part of the sacral plexus (Suprasacral Parallel Shift, SSPS) to achieve analgesia of the femoral nerve, the obturator nerve, the lumbosacral trunk, and spinal nerve L1 with SSPS guided by ultrasound/MR image fusion vs. SSPS guided by ultrasound by estimating sensory block of in healthy volunteers by estimating the sensory block of dermatomes of the terminal nerves in healthy volunteers.

The secondary objective is to estimate a) preparation and b) procedure time, c) injection site and d) depth, e) discomfort, f) change in MAP, g) plasma lidocaine pharmacokinetics, h) motor and i) sensory block, j) perineural and k) epidural spread of lidocaine-epinephrine added gadotorate meglumine on MRI, and l) cost-effectiveness of SSPS guided by ultrasound/MR image fusion vs. SSPS guided by ultrasound.

The investigators hypothesize that block success is higher for SSPS guided by ultrasound/MR image fusion than for SSPS guided by ultrasound.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  • Age ≥ 18 years
  • Volunteers who has given their written and oral informed consent to participate in the study after having fully understood the content and the limitations of the protocol.
  • Normal healthy person (American Society of Anesthesiology [ASA] Classification I)
Exclusion Criteria
  • Volunteers not able to cooperate in the study
  • Volunteers not able to understand or speak Danish
  • Daily use of analgesics
  • Allergy against the medicines used in the study
  • Drug abuse (according to the investigator's judgement)
  • Alcohol consumption greater than the recommendations of the Danish National Board of Health
  • Contraindication for MRI including pregnancy
  • Volunteer in whom nerve blocks are not possible due to technical reasons
  • Volunteer who are incompetent (ie. surrogate consent is not accepted)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Suprasacral Parallel Shift guided by US/MR image fusionLidocaine-epinephrine added gadoterate meglumineUse of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
Suprasacral Parallel Shift guided by USLidocaine-epinephrine added gadoterate meglumineUse of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
Primary Outcome Measures
NameTimeMethod
Block successEstimated 40 min after completed intervention. Presented 10 months after last patient last visit (LVLP).

Block success of the clinical relevant lumbosacral nerves that innervate the hip joint capsule estimated as significant motor block of the obturator nerve, the femoral nerve, and the lumbosacral trunk. Motor block is a significant proxy marker of sensory block. Motor block (muscle strength, mmHg) is assessed with a handheld dynamometer.

Secondary Outcome Measures
NameTimeMethod
Block procedure timeEstimated during intervention. Presented 10 months after LVLP

Block procedure time in seconds is defined as the time of the placement of the ultrasound probe on the skin to until the block needle is pulled out after injection of local anesthetics

Injection siteEstimated at the end of the intervention. Presented 10 months after LVLP
Mean arterial pressure changeMean arterial pressure is measured prior intervention and 5 min after intervention. Presented 10 months after LVLP
Plasma lidocaineBlood samples are withdrawn 0, 5, 10, 20, 40, 60, and 90 minutes after intervention. Presented 10 months after LVLP
Time for preparationEstimated prior to intervention. Presented 10 months after LVLP

Time for preparation in seconds is defined as the time of placement of the volunteer on the bed until the end of pre-ultrasound scanning

Block needle depthEstimated at the end of the intervention. Presented 10 months after LVLP
DiscomfortEstimated immediately after the intervention. Presented 10 months after LVLP

Estimated on numeric rating scale 0-10

Sensory (cold, warm, touch, pain) block of the dermatomes T12-S3 and the lateral femoral cutaneous nerveEstimated 50 min after intervention. Presented 10 months after LVLP
Perineural spread of local anesthetics added gadoterate meglumineEstimated on MRI sampled 10-30 minutes after intervention. Presented 10 months after LVLP
Epidural spread of local anesthetics added gadoterate meglumineEstimated on MRI sampled 10-30 minutes after intervention. Presented 10 months after LVLP
Cost-effectiveness (ICER)Calculated after LVLP. Presented 10 months after the last visit of the last volunteer

ICER is estimated as the difference in mean marginal cost of the blocks.

Trial Locations

Locations (1)

Department of Anesthesiology and Intensive Care, Aarhus University Hospital

🇩🇰

Aarhus C, Denmark

Department of Anesthesiology and Intensive Care, Aarhus University Hospital
🇩🇰Aarhus C, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.